Chris Degnan

This profile gathers the share dealings of Chris Degnan across 3 companies, led by UroGen Pharma Ltd., Galera Therapeutics, Inc. and Verrica Pharmaceuticals Inc. Between 19 June 2018 and 8 October 2026, the trades on record add up to 6 filings.

In open-market terms, that means 2 purchases worth €57k on one side and 2 sales worth €104k on the other. Sales outweigh purchases by €47k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 9 October 2026, the filings show an option exercise in UroGen Pharma Ltd. The last insider purchase was made public on 14 March 2023, 1,320 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.